LHLABORATORY CORP OF AMERICA ...

NYSE labcorp.com


$ 198.31 $ 0.05 (0.03 %)    

Friday, 26-Apr-2024 15:59:57 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 198.4
$ 197.86
$ 0.00 x 0
$ 0.00 x 0
$ 197.60 - $ 200.00
$ 177.96 - $ 233.32
931,317
na
17.56B
$ 1.10
$ 42.01
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-26-2024 12-31-2023 10-K
2 10-30-2023 09-30-2023 10-Q
3 08-04-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-01-2022 09-30-2022 10-Q
7 08-01-2022 06-30-2022 10-Q
8 04-29-2022 03-31-2022 10-Q
9 02-25-2022 12-31-2021 10-K
10 11-02-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 10-29-2020 09-30-2020 10-Q
15 07-31-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 02-28-2020 12-31-2019 10-K
18 10-31-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-03-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 10-30-2018 09-30-2018 10-Q
23 07-27-2018 06-30-2018 10-Q
24 05-01-2018 03-31-2018 10-Q
25 02-27-2018 12-31-2017 10-K
26 11-02-2017 09-30-2017 10-Q
27 08-02-2017 06-30-2017 10-Q
28 04-28-2017 03-31-2017 10-Q
29 02-27-2017 12-31-2016 10-K
30 10-28-2016 09-30-2016 10-Q
31 07-29-2016 06-30-2016 10-Q
32 05-06-2016 03-31-2016 10-Q
33 02-29-2016 12-31-2015 10-K
34 10-30-2015 09-30-2015 10-Q
35 07-30-2015 06-30-2015 10-Q
36 05-04-2015 03-31-2015 10-Q
37 02-26-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 07-29-2014 06-30-2014 10-Q
40 04-29-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-buy-on-laboratory-corp-lowers-price-target-to-255

Truist Securities analyst Ryan MacDonald maintains Laboratory Corp (NYSE:LH) with a Buy and lowers the price target from $27...

 barclays-maintains-equal-weight-on-laboratory-corp-lowers-price-target-to-213

Barclays analyst Stephanie Davis maintains Laboratory Corp (NYSE:LH) with a Equal-Weight and lowers the price target from $2...

 baird-maintains-outperform-on-laboratory-corp-lowers-price-target-to-244

Baird analyst Eric Coldwell maintains Laboratory Corp (NYSE:LH) with a Outperform and lowers the price target from $255 to $...

 labcorps-q1-revenue-surpasses-forecasts-analysts-scrutinize-invitae-deal

Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sale...

 laboratory-corp-q1-2024-adj-eps-368-beats-348-estimate-sales-3177b-beat-3117b-estimate

Laboratory Corp (NYSE:LH) reported quarterly earnings of $3.68 per share which beat the analyst consensus estimate of $3.48 by ...

Core News & Articles

Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requ...

 labcorp-reports-strategic-expansion-of-its-precision-oncology-portfolio

Labcorp is expanding its portfolio of solutions that support the development of novel therapies for oncology with the launch of...

 labcorp-launches-labcorp-plasma-detect-extending-leadership-into-molecular-residual-disease-mrd-clinical-research

The launch of the Labcorp Plasma Detect MRD solution further enhances Labcorp's leadership in precision oncology across the...

 labcorp-expands-diagnostic-reach-with-strategic-deal-for-select-assets-of-bioreference-health

Labcorp acquires certain operations of Opko Health subsidiary BioReference Health. The assets Labcorp is acquiring generate abo...

Core News & Articles

Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical l...

 argus-research-upgrades-laboratory-corp-to-buy

Argus Research analyst David Toung upgrades Laboratory Corp (NYSE:LH) from Hold to Buy.

 reported-saturday-labcorp-presented-new-research-demonstrating-clinical-impact-of-precision-diagnostics-in-guiding-biomarker-targeted-therapies-for-patients-with-epithelial-ovarian-cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice

 labcorp-introduces-its-weight-loss-management-portfolio

The new offering features educational resources and convenient testing solutions, equipping individuals and their physicians wi...

 leerink-partners-initiates-coverage-on-laboratory-corp-with-outperform-rating-announces-price-target-of-260

Leerink Partners analyst Michael Cherny initiates coverage on Laboratory Corp (NYSE:LH) with a Outperform rating and announc...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION